Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2015 · 10-Q
Revenue$6.29M$6.29M+51.9% vs Q3 2014 Net Income-$3.72K-$3.72KN/M vs Q3 2014 EPS Diluted$0.00$0.00N/M vs Q3 2014 Gross Profit$2,481,630+62.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Free Cash Flowderived-$863,989N/M Margins · derivedGross margin39.5%+2.7 pt vs Q3 2014
Operating margin2.8%+18.5 pt vs Q3 2014
Net margin-0.1%+15.9 pt vs Q3 2014
ended Oct 3, 2015 · filed Nov 12, 2015 · 40 d after period end